Palbociclib plus letrozole clinical outcomes PALOMA-2

In PALOMA-2, palbociclib plus letrozole significantly improved progression-free survival by 13 months compared to letrozole alone (27.6 vs 14.5 months) with manageable hematologic toxicity and maintained quality of life, but did not demonstrate a significant overall survival benefit after 90 months of follow-up.

Abstract

The PALOMA-2 trial demonstrated that palbociclib plus letrozole significantly improved progression-free survival compared to placebo plus letrozole in postmenopausal women with ER+/HER2- advanced breast cancer. Median PFS was 27.6 months versus 14.5 months (HR 0.56, P<0.0001), with consistent benefit observed across all patient subgroups including Asian patients (25.7 vs 13.9 months, HR 0.49, P=0.007) and those with low disease burden. Notably, PFS improvement occurred regardless of objective response status, with non-responders experiencing median PFS of 10.9 versus 5.6 months (HR 0.72, P=0.016). The treatment delayed time to subsequent chemotherapy by approximately 10 months (40.4 vs 29.9 months). However, after 90.1 months of follow-up, median overall survival was 53.9 versus 51.2 months (HR 0.96, P=0.34), showing no significant improvement.

The primary toxicity was hematologic, with grade 3-4 neutropenia occurring in 66.4% of patients (vs 1.4% with placebo), increasing to 89.2% in Asian populations. Despite this, febrile neutropenia remained rare (1.8-2.0%), and treatment discontinuation rates were low (9.7-12.2% vs 5.9%). Quality of life was maintained with no significant differences in FACT-Breast Total or EQ-5D scores between treatment arms, and pain scores significantly improved with palbociclib plus letrozole (P=0.0183). Neutropenia did not negatively impact quality of life measures.

Methods

We analyzed 10 sources from an initial pool of 200, using 6 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question.

Paper search

We performed a semantic search across over 138 million academic papers from the Elicit search engine. We ran this query: "Palbociclib plus letrozole clinical outcomes PALOMA-2". The search returned 200 total results from Elicit.

Screening

We screened in sources based on their abstracts that met these criteria:

• PALOMA-2 Trial Relevance: Does this study report on the PALOMA-2 trial (NCT01740427) or its secondary/post-hoc analyses?
• Patient Population: Does this study include patients with hormone receptor-positive, HER2-negative advanced breast cancer?
• Clinical Outcomes: Does this study report clinical efficacy outcomes (progression-free survival, overall survival, objective response rate, clinical benefit rate), safety and tolerability outcomes, quality of life analyses, or is it a systematic review/meta-analysis that includes PALOMA-2 data?
• Intervention Specificity: Does this study focus on palbociclib plus letrozole combination therapy (rather than palbociclib with other endocrine partners or palbociclib monotherapy)?
• Disease Population Specificity: Does this study focus on the appropriate breast cancer population (not exclusively triple-negative, HER2-positive, or early-stage disease)?
• Study Design Appropriateness: Is this study a clinical study in humans (not preclinical, in vitro, animal studies, case reports, or case series)?

Data extraction

We asked a large language model to extract each data column below from each paper.

• Efficacy Outcomes:
  • Progression-free survival (median PFS in months, hazard ratio, 95% CI, p-value)
  • Overall survival (median OS in months, hazard ratio, 95% CI, p-value if reported)
  • Objective response rate (ORR as percentage, 95% CI)

Efficacy Outcomes

Progression-Free Survival

Across all analyses, palbociclib plus letrozole demonstrated consistent improvement in PFS compared to placebo plus letrozole. In the primary analysis, median PFS was 24.8 months versus 14.5 months (HR 0.58, 95% CI 0.46-0.72, P<0.001). With extended follow-up of approximately 38 months, median PFS was 27.6 months versus 14.5 months (HR 0.56, P<0.0001), confirming the sustained benefit.

Overall Survival

After a median follow-up of 90.1 months, median OS was 53.9 months (95% CI 49.8-60.8) with palbociclib plus letrozole versus 51.2 months (95% CI 43.7-58.9) with placebo plus letrozole (HR 0.96, 95% CI 0.78-1.18, one-sided P=0.34). The study did not demonstrate a statistically significant improvement in OS. An imbalance in patients with unknown survival status (13.3% vs 21.2%) limited interpretation.

Safety Outcomes

Hematologic Toxicities

Neutropenia was the most common adverse event, occurring in 66.4% of patients (grade 3-4) in the palbociclib-letrozole arm versus 1.4% in the placebo-letrozole arm. Febrile neutropenia was rare, occurring in 1.8-2.0% of patients receiving palbociclib plus letrozole and 0% receiving placebo plus letrozole.

Patient-Reported Outcomes and Quality of Life

Patient-reported outcomes were assessed using the Functional Assessment of Cancer Therapy-Breast (FACT-Breast) and EuroQol 5 dimensions (EQ-5D) questionnaires. The addition of palbociclib to letrozole maintained health-related QOL and improved pain scores compared to letrozole alone.

Synthesis

The PALOMA-2 trial consistently demonstrated progression-free survival benefit with palbociclib plus letrozole across multiple follow-up analyses and patient subgroups, while overall survival did not reach statistical significance. This apparent discordance between PFS and OS outcomes merits mechanistic explanation.